Business Context and Reporting Period
This Form 8-K is filed by JATT Acquisition Corp (JATT), a Cayman Islands-based special purpose acquisition company (SPAC), on March 14, 2023, reporting events occurring on March 13, 2023. The filing details the final stages of the proposed business combination with Zura Bio Ltd, a biopharmaceutical company incorporated in England and Wales. JATT is currently listed on the New York Stock Exchange (NYSE) under the symbols JATT, JATT WS, and JATT U.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the reporting period. The only specific financial transaction disclosed is a private placement:
- Subscription Agreement: JATT entered into an agreement with an unaffiliated accredited investor for 9,950 Class A ordinary shares.
- Price per Share: $10.00.
- Aggregate Proceeds: $99,500.
- Closing Condition: The transaction is contingent upon the closing of the Business Combination with Zura Bio.
Debt, liquidity, and margin metrics are not disclosed in this document.
Material Changes
The primary material change reported is the strategic decision to transfer the listing of JATT's securities from the NYSE to the Nasdaq Stock Market LLC. This transfer is scheduled to occur in connection with, and upon the closing of, the Business Combination with Zura Bio. Additionally, the company has secured a small private placement of capital to support the transaction.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management anticipates the completion of the Business Combination, which will result in the combined entity listing on Nasdaq. The filing includes standard forward-looking statements regarding the anticipated financial impacts and timing of the combination, noting these are subject to significant risks.
Risks and Contingencies: The filing outlines numerous risks that could prevent the transaction from closing or alter its outcome, including:
- Failure to obtain shareholder approval or necessary regulatory approvals.
- Inability to satisfy the minimum cash requirement following shareholder redemptions.
- Failure to close the concurrent private placement of ordinary shares.
- Expiration of the Business Combination deadline without an extension.
- Intellectual property disputes, cybersecurity risks, and competitive pressures in the biopharmaceutical industry.
- Macroeconomic factors and the ongoing impact of the global COVID-19 pandemic.
Investor Verification Checklist
- Verify the status of shareholder approval for the Business Combination with Zura Bio.
- Confirm the final listing date and ticker symbols on Nasdaq post-combination.
- Review the Form S-4 for detailed financial projections and risk factors specific to Zura Bio.
- Monitor the redemption rate of JATT public shares to ensure the minimum cash requirement is met.
- Check for any updates on regulatory approvals required for the merger.